Pharma Blog Review

Jupiter’s gravity, and a brewing political battle

November 14, 2008 – 1:42 pm

Sort of a slow week, but interesting things did happen. The biggest news of the week was the results of AstraZeneca’s Jupiter study, and everyone seems to be debating about how the results will affect Crestor sales and the use of statins (even as some say it’s a boost, CEO David Brennan is urging caution, [...]

Posted in Uncategorized | No Comments »

A new president, a look at the future, but the world goes on

November 7, 2008 – 3:51 am

Yes, Barack Hussein Obama will be the 44th president of the United States, once he is sworn into office in January. Now that the election is over and Mr. Obama is already starting to pick staff members, we can all go back to our daily lives. Other things did happen this week: The Supreme Court [...]

Posted in Uncategorized | 1 Comment »

Science ignorance, Avandia attacked again, and more about pre-emption

October 31, 2008 – 4:41 pm

Yes, it’s Halloween today. Hopefully you will find this roundup full of treats, not tricks. PharmaGossip knows how to celebrate (do you recognize anyone?). This was a fairly quiet week, as the countdown narrows for the U.S. presidential elections. There was some interesting news: Wyeth, like many other pharma companies, is narrowing its R&D focus; [...]

Posted in Uncategorized | 2 Comments »

Merck job cuts, Acomplia sales suspended, and other bits

October 24, 2008 – 3:52 pm

It started off as a nice quiet week, but then Merck reported that it would be shedding 7,200 jobs and closing three research labs, with 40% of the job cuts coming from the United States. Europe suspended sales of the antiobesity drug Acomplia. And the New York Times reported that drug prescriptions were down and [...]

Posted in Uncategorized | No Comments »

The ongoing healthcare debate and my own braindump

October 17, 2008 – 2:24 pm

Yes, I watched the final Barack Obama/John McCain debate on Wednesday night. Thankfully, the election will be over soon, and my dad will stop forwarding me “interesting” e-mails (he’s a conservative ex-cop; just one guess who he supports). U.S. presidential politics have made some headway into the pharmaceutical blogosphere; John Mack reported the results of [...]

Posted in Uncategorized | No Comments »

Lilly spends money, Pfizer struggles, and a KOL gets KO’d

October 9, 2008 – 3:29 pm

There’s a lot of news this week being discussed. Lilly turned out to be the secret suitor of ImClone and is buying the company for $6.5 billion, as well settling with 33 states for $62 million over claims of improperly marketing Zyprexa; Pfizer’s doing a reorganization of its research units and has been accused of [...]

Posted in Uncategorized | 1 Comment »